retatrutide fda approval The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

Pfizer, Novo Nordisk bidding war is just the latest escalation of a lucrative GLP 1 race GLP 1 drug could offer relief to migraine sufferers The Emerging Role of Glucagon Like Peptide 1 Receptor Agonists for the Treatment of Metabolic Dysfunction Associated Steatohepatitis Clinical Gastroenterology and Hepatology Untitled Nearly 30% average weight loss from a weekly injection., Retatrutide could represent the next major step in obesity treatment, but it remains investigational, and long term safety, monitoring and